Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538656 | 0.92 | CA14 (0.39) | HDAC6CA14SMN1; SMN2NR1I2PGR | |
| SCHEMBL14639322 | 0.87 | HDAC6 (0.35) | HDAC6CA14SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1440925 | 0.87 | ALDH1A1 (0.38) | HDAC6CA14SMN1; SMN2NR1I2PGR | |
| SCHEMBL15645124 | 0.85 | CA14 (0.44) | HDAC6CA14HDAC1HDAC2ALDH1A1 | |
| SCHEMBL20045144 | 0.84 | CA14 (0.39) | HDAC6CA14SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL1272960 | 0.84 | CA14 (0.49) | HDAC6CA14SMN1; SMN2NR1I2PGR | |
| SCHEMBL25247476 | 0.82 | CA14 (0.41) | HDAC6CA14HDAC1HDAC2ALDH1A1 | |
| SCHEMBL15312506 | 0.81 | SMN1; SMN2 (0.38) | HDAC6CA14SMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL21425191 | 0.81 | CA14 (0.38) | HDAC6CA14HDAC1HDAC2CTSK | |
| SCHEMBL6538907 | 0.80 | CA14 (0.46) | HDAC6CA14SMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | INSMED INCORPORATED (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4646265-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | UNIV CALIFORNIA (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4452416-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118786129-A | Covalent binding inhibitors of G12S, G D and/or G12E mutants of K-RAS GTPases | 加利福尼亚大学董事会 | 2024-10-15 | — | — | CN | disclosed |
| WO-2024148308-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148308-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2023122662-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122662-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | WO | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | KRAS, HRAS, NRAS | HDAC6 1346/4885CA14 4606/4885SMN1; SMN2 4083/4885 |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP7, DPP9 | HDAC6 578/4885CA14 1092/4885SMN1; SMN2 880/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | HDAC6 3137/4885CA14 1446/4885SMN1; SMN2 2439/4885 |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | DPP4, DPP7, DPP9 | HDAC6 578/4885CA14 1092/4885SMN1; SMN2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.